From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
Group | HPV16 | HPV18 | HPV58 | ||||||
---|---|---|---|---|---|---|---|---|---|
CD4+ | CD8+ | CD4+/CD8+ | CD4+ | CD8+ | CD4+/CD8+ | CD4+ | CD8+ | CD4+/CD8+ | |
PBS group | 19.920 + 1.069 | 7.730 + 0.098 | 2.578 + 0.153 | 20.757 + 0.886 | 10.747 + 0.225 | 1.933 + 0.122 | 21.660 + 0.938 | 5.583 + 0.170 | 3.881 + 0.198 |
AD-NC group | 17.110 + 0.503 | 7.357 + 0.981a | 2.354 + 0.317 | 18.497 + 0.657a | 12.253 + 1.762 | 1.526 + 0.169a | 17.577 + 1.509a | 6.287 + 1.227 | 2.870 + 0.630a |
Vaccine group | 17.493 + 0.287a,b | 9.560 + 0.310a | 1.832 + 0.081a,b | 15.633 + 0.329a,b | 15.833 + 0.761a,b | 0.989 + 0.052a,b | 16.583 + 0.497a | 12.047 + 0.345a,b | 1.377 + 0.020a,b |